Priliximab

Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease^[1] and multiple sclerosis^[2]^[3] but has not yet received U.S. Food and Drug Administration licensing. The patent belongs to the biotechnology company Centocor.

References

^ Stronkhorst A, Radema S, Yong S, Bijl H, ten Berge I, Tytgat G, van Deventer S (1997). "CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study". Gut. 40 (3): 320–7. doi:10.1136/gut.40.3.320. PMC 1027080. PMID 9135519.
^ Llewellyn-Smith N, Lai M, Miller D, Rudge P, Thompson A, Cuzner M (1997). "Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412". Neurology. 48 (4): 810–6. doi:10.1212/wnl.48.4.810. PMID 9109860. S2CID 9938490.
^ van Oosten B, Lai M, Hodgkinson S, Barkhof F, Miller D, Moseley I, Thompson A, Rudge P, McDougall A, McLeod J, Adèr HJ, Polman C (1997). "Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial". Neurology. 49 (2): 351–7. doi:10.1212/wnl.49.2.351. PMID 9270561. S2CID 8294890.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.